# Neotx Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neotx-holdings

- Industry: Biotechnology
- Headquarters: Rehovot, Israel
- Website: www.neotx.com
- Total disclosed funding: $18M
- Latest round: Series B (Dec 1, 2017)
- Investors on record: 1

## About

Neotx Holdings Ltd. is focused on developing innovative cancer therapeutics, emphasizing immunotherapy solutions that enhance the body's capacity to combat cancer. The company aims to deliver proprietary therapies to healthcare professionals and institutions involved in oncology.Neotx Holdings Ltd. is engaged in the development of cancer therapeutics, particularly immunotherapy solutions. Founded in 2015, the company is headquartered in Rehovot, Israel. Asher Nathan leads the company and has a history in the biotechnology sector. Neotx has successfully completed a total of 3 deals, with the most recent funding round being a Series C round in February 2020, raising USD 45 mn, which accounts for the total amount raised by the company.Neotx specializes in innovative cancer therapeutics, particularly focusing on immunotherapy solutions designed to enhance the body’s natural ability to fight cancer. The company offers proprietary therapies aimed at targeting cancer cells effectively while minimizing damage to healthy tissues. Their products are designed for oncologists and healthcare institutions, and they are marketed in North America and Europe to various healthcare providers dedicated to oncology, addressing challenges such as resistance to existing therapies and the need for personalized treatment plans.Neotx generates revenue through strategic partnerships and collaborations with healthcare institutions and pharmaceutical companies. The company provides its therapies to hospitals, clinics, and research facilities specializing in cancer treatment. Revenues include direct sales of immunotherapy products and potential licensing agreements for the use of proprietary technology, structured to accommodate various pricing models that ensure access for healthcare providers to necessary treatments. The company’s flagship therapies are positioned as premium offerings aimed at delivering clinical benefits to patients, supporting the organization’s revenue framework.Following the Series C funding round in February 2020, in which Neotx raised USD 45 mn, the company is set to leverage these resources to accelerate product development and market expansion. Neotx is focusing on launching new immunotherapy products designed to address specific cancer treatment challenges, with plans to enter additional markets in Europe and North America by 2023. The recent funding will support these initiatives, allowing the company to enhance its offerings and reach a broader base of healthcare providers.

## Funding rounds

- Series B, Dec 1, 2017, $8.8M — Starr Investment Holdings
- Series A, Oct 1, 2016, $9.2M — Starr Investment Holdings

## Investors

- Starr Investment Holdings (https://capitalatlas.ai/funds/starr-investment-holdings) — Series A, Series B